EMA backs standard approval of two Covid-19 vaccines

The European Medicines Agency’s expert committee now supports full authorization of Moderna and Pfizer-Biontech’s vaccines, which have so far only been conditionally approved.

Photo: Hannah Beier/Reuters/Ritzau Scanpix

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its positive recommendation for the standard authorization of the Covid-19 vaccines developed by Moderna and the Pfizer-Biontech partnership, a press release announces.

The two vaccines, Comirnaty and Spikevax, were granted conditional marketing authorization at the time of approval, a stamp usually given to medicines that patients need urgently, and for which there therefore aren’t a complete data set when it comes to effects and potential side-effects. Such an approval is only given if the safety and efficacy of the drug theoretically exceed the theoretical risk of not having all data.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs